NMTR News and Press, 9 Meters Biopharma Inc. From 03/14/23

2023-03-14 08:34:23 ET GitLab ( GTLB ) -30% on Q4 earnings release . Cingulate ( CING ) -11% . 9 Meters Biopharma ( NMTR ) -9% after proposes to raise $5M in stock offering . BigBear.ai ( BBAI ) -9% on Q4 earnings release . B...

2023-03-14 08:11:08 ET 9 Meters Biopharma ( NASDAQ: NMTR ) entered into a definitive securities purchase agreement for the purchase and sale of 3.12M shares and warrants to purchase 6.25M shares at a combined purchase price of $1.60/share and accompanying warrant. War...

RALEIGH, NC / ACCESSWIRE / March 14, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it has entered into a definitive securities purchase agreement for the purchase a...

2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...

RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to...

RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled ...

Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependence Study design allows for the assessment of the entirety of the short bowel syndrome patient population US IRB approval secu...

Collaboration focuses on the relationship between intestinal microbiome composition and systemic responses to cancer treatments and builds upon additional positive preclinical data with investigational agent NM-102 IND-enabling pathway for NM-102 underway with indication selection anti...

9 Meters Biopharma press release ( NASDAQ: NMTR ): Q3 GAAP EPS of -$0.72 beats by $0.10 . As of September 30, 2022, the company's cash and cash equivalents totaled approximately $39.4M and is sufficient to fund the ongoing clinical programs into the second half of 2023...

Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimen Clinical plans and activities are underway including site and patient recruitment to facilitat...